Genelabs To Meet With FDA Following Positive Open-Label Prestara Study
This article was originally published in The Pink Sheet Daily
Executive Summary
The study was an extension of a previous Phase III study that failed to meet its primary endpoint of increased bone mineral density at the lumbar spine.
You may also be interested in...
La Jolla Proceeds With Additional Riquent Dosing Study
High doses of lupus agent appear to be "well-tolerated" in healthy volunteers, firm says. Dose-response data are being collected in response to FDA's "approvable" letter. La Jolla plans to add the information to ongoing pivotal trial.
Genelabs' Prestara Phase III Does Not Confirm Bone Mineral Density Effect
The trial was designed to meet FDA's "approvable" letter request for confirmation of bone mineral density increases in women with lupus receiving glucocorticoids. Genelabs plans to meet with the agency when it completes data analysis.
Barr’s Expanded Thalidomide ANDA Could Increase Likelihood Of A Marketed Generic
Amended application includes 50 mg and 100 mg dosage forms, which are used in multiple myeloma.